BISHOP, CHARLES W.,CRAWFORD, KEITH H.,MESSNER, ERIC J.
申请号：
CA2624897
公开号：
CA2624897C
申请日:
2006.10.12
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
A controlled-release pha.pi.naceutical formulation including cholecalciferoland/or ergocalciferol, a method of making the formulation, and a method ofadministering the formulation to treat 25-hydroxyvitamin D insufficiency ordeficiency, are disclosed. The composition and method of administrationpreferably result in delayed release of the ~ vitamin(s) in the ileum of thesmall intestine and sustained, substantially constant, release of thevitamin(s) over an extended period, e.g., at least 4 hours or more. Individualand combined dosages of 500 IU to 50,000 IU per dosage form, preferably daily,are disclosed. The compositions and methods are contemplated to exhibit one ormore advantages including, but not limited to efficiency of vitamin Drepletion and maintenance； mitigation or avoidance of first pass effects ofthe Vitamin D compounds on the duodenum； mitigation or avoidance of adversesupraphysiological surges in intralumenal, intracellular and blood levels ofcholecalciferol, ergocalciferol and 25- hydroxyvitamin D and theirconsequences； and mitigation or avoidance of serious side effects associatedwith Vitamin D supplementation, namely Vitamin D toxicity.
